-
公开(公告)号:US20240246971A1
公开(公告)日:2024-07-25
申请号:US18584672
申请日:2024-02-22
Applicant: Chugai Seiyaku Kabushiki Kaisha
Inventor: Hitoshi YOSHINO , Satoshi TSUCHIYA , Atsushi MATSUO , Tsutomu SATO , Masahiro NISHIMOTO , Kyoko OGURI , Hiroko OGAWA , Yoshikazu NISHIMURA , Yoshiyuki FURUTA , Hirotaka KASHIWAGI , Nobuyuki HORI , Takuma KAMON , Takuya SHIRAISHI , Shoshin YOSHIDA , Takahiro KAWAI , Satoshi TANIDA , Masahide AOKI
IPC: C07D471/04 , A61K31/437 , A61K31/444 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/5386 , A61P1/16 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/10 , A61P25/16 , A61P25/28 , C07D519/00
CPC classification number: C07D471/04 , A61K31/437 , A61K31/444 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/5386 , A61P1/16 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/10 , A61P25/16 , A61P25/28 , C07D519/00
Abstract: The present invention provides a compound having the basic structure shown by Formula (I) in which the indole ring and the pyrazolopyridine structure is bound through a substituent, a salt thereof or a solvate of either the compound or a salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound, salt or solvate as an active ingredient.
-
公开(公告)号:US20240216355A1
公开(公告)日:2024-07-04
申请号:US18471563
申请日:2023-09-21
Applicant: Monte Rosa Therapeutics, Inc.
Inventor: Bernhard Fasching , Gerald Gavory , Lev Osherovich
IPC: A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/4995 , A61K31/5377 , A61K31/5386 , A61K31/7048 , A61P11/00 , A61P35/00
CPC classification number: A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/4995 , A61K31/5377 , A61K31/5386 , A61K31/7048 , A61P11/00 , A61P35/00
Abstract: The present disclosure relates to a compound of formula I or a pharmaceutically acceptable salt thereof
wherein A is
X1 is linear or branched C1-6 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, 4-8 membered heterocycloalkyl, wherein X1 is unsubstituted or substituted with one or more of halogen, linear or branched C1-6 alkyl, linear or branched C1-6 heteroalkyl, CF3, CHF2, CMeF2, —O—CHF2, —O—(CH2)2—OMe, OCF3, C1-6 alkylamino, —CN, —N(H)C(O)—C1-6alkyl, —OC(O)—C1-6alkyl, —OC(O)—C1-4alkylamino, —C(O)O—C1-6alkyl, —COOH, —CHO, —C1-6alkylC(O)OH, —C1-6alkylC(O)O—C1-6alkyl, NH2, C1-6 alkoxy or C1-6 alkylhydroxy; or X1 together with X4 forms a 4-8 membered heterocycloalkyl, which is unsubstituted or substituted with one or more of halogen, linear or branched —C1-6 alkyl, CF3, CHF2, CMeF2, —O—(CH2)2—OMe, OCF3, OCHF2, C1-6 alkylamino, —CN, —N(H)C(O)—C1-6alkyl, —OC(O)—C1-6alkyl, —C(O)O—C1-6alkyl, —COOH, —C1-6alkylC(O)OH, —C1-6alkylC(O)O—C1-6alkyl, NH2, C1-4 alkylhydroxy, or C1-6 alkoxy; X2 is hydrogen, C3-6 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, 4-8 membered heterocycloalkyl, wherein X2 is unsubstituted or substituted with one or more of linear or branched C1-6 alkyl, —C1-4 alkoxy, NH2, NMe2, halogen, CF3, CHF2, CMeF2, —O—(CH2)2—OMe, OCF3, OCHF2, C1-4 alkylhydroxy; X3 is —NH—, —O—; X4 is —NH—, —CH2—; L1 is a covalent bond, C1-6 alkyl, which is unsubstituted or substituted with one or more of C1-4 alkyl, halogen; L2 is a covalent bond, C1-6 alkyl, which is unsubstituted or substituted with one or more of C1-4 alkyl, halogen; L3 is a covalent bond, —O—, —C1-4 alkoxy or C1-6 alkyl, which is unsubstituted or substituted with one or more of C1-4 alkyl, halogen, for use in the prevention and treatment of a disease or disorder caused by or associated with one or more premature termination codons in a monotherapy or in a combined therapy with an aminoglycoside or a pharmaceutically acceptable salt thereof.-
公开(公告)号:US20240208994A1
公开(公告)日:2024-06-27
申请号:US18556231
申请日:2022-04-18
Applicant: Merck Sharp & Dohme LLC
Inventor: Alan C. Cheng , Ying-Duo Gao , Song Yang , Mihir Mandal , Jiafang He , Jovan Alexander Lopez , Maoqun Tian
IPC: C07D498/10 , A61K31/5386 , A61K45/06
CPC classification number: C07D498/10 , A61K31/5386 , A61K45/06
Abstract: The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.
-
公开(公告)号:US11986471B2
公开(公告)日:2024-05-21
申请号:US17338579
申请日:2021-06-03
Applicant: Tango Therapeutics, Inc.
Inventor: Kevin M. Cottrell , John P. Maxwell , Douglas A. Whittington
IPC: A61K31/4725 , A61K31/496 , A61K31/5377 , A61K31/5386 , C07D401/14 , C07D413/14 , C07D498/08
CPC classification number: A61K31/4725 , A61K31/496 , A61K31/5377 , A61K31/5386 , C07D401/14 , C07D413/14 , C07D498/08
Abstract: Compounds are provided according to Formula (I):
and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X1, X2, X3, X4, Y, A, L1, L2, R1, R2, R5, m and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.-
85.
公开(公告)号:US20240076281A1
公开(公告)日:2024-03-07
申请号:US18070408
申请日:2022-11-28
Applicant: Arvinas Operations, Inc.
Inventor: Yimin QIAN , Hanqing DONG , Jing WANG
IPC: C07D401/14 , A61K31/454 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/519 , A61K31/5386 , A61K31/551 , A61K38/05 , A61K38/06 , A61K45/06 , A61K47/54 , A61P15/00 , A61P35/00 , C07D401/04 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D498/10 , C07K5/078 , C07K5/083
CPC classification number: C07D401/14 , A61K31/454 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/519 , A61K31/5386 , A61K31/551 , A61K38/05 , A61K38/06 , A61K45/06 , A61K47/54 , A61K47/545 , A61P15/00 , A61P35/00 , C07D401/04 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/08 , C07D487/10 , C07D498/10 , C07K5/06165 , C07K5/0806 , C07K5/06034
Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, inhibitors of apoptosis proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
-
公开(公告)号:US11878972B2
公开(公告)日:2024-01-23
申请号:US17125012
申请日:2020-12-17
Applicant: TORQUR AG , UNIVERSITÄT BASEL
Inventor: Denise Rageot , Paul Hebeisen , Florent Beaufils , Doriano Fabbro , Petra Hillmann-Wüllner , Hoa Huu Phuc Nguyen , Wolfgang Löscher , Claudia Brandt , Alexander Markus Sele
IPC: C07D413/14 , A61P25/28 , A61P25/08 , C07D417/14 , C07D451/02 , C07D451/14 , C07D498/08 , C07D519/00 , A61K31/5386 , A61K31/541 , A61K31/5377 , A61K31/53
CPC classification number: C07D413/14 , A61K31/53 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61P25/08 , A61P25/28 , C07D417/14 , C07D451/02 , C07D451/14 , C07D498/08 , C07D519/00
Abstract: The present invention is relates to a compound of formula (I),
wherein
X1, X2 and X3 are, independently of each other, N or CH; with the proviso that at least two of
X1, X2 and X3 are N;
Y is N or CH;
R1 and R2 are independently of each other
(iii) a morpholinyl of formula (II)
wherein the arrow denotes the bond in formula (I); and
wherein R3 and R4 are independently of each other H, C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxy, C1-C2alkoxyC1-C3alkyl, CN, or C(O)O—C1-C2alkyl; or R3 and R4 form together a bivalent residue —R5R6— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2—O—CH2—, —CH2—NH—CH2—, or any of the structures
wherein the arrows denote the bonds in formula (II); or
(iv) a saturated 6-membered heterocyclic ring Z selected from thiomorpholinyl and piperazinyl, optionally substituted by 1 to 3 R7; wherein R7 is independently at each occurrence C1-C3alkyl optionally substituted with one or two OH, C1-C2fluoroalkyl, C1-C2alkoxyC1-C3alkyl, C3-C6cycloalkyl; or two R 7 substituents form together a bivalent residue —R8R9— selected from C1-C3alkylene optionally substituted with 1 to 4 F, —CH2—O—CH2— or —O—CH2CH2—O—;
with the proviso that at least one of R1 and R2 is a morpholinyl of formula II;
and prodrugs, metabolites, tautomers, solvates and pharmaceutically acceptable salts thereof,
for use in the prevention or treatment of a neurological disorder in a subject.-
公开(公告)号:US11814381B2
公开(公告)日:2023-11-14
申请号:US17065122
申请日:2020-10-07
Applicant: Chugai Seiyaku Kabushiki Kaisha
Inventor: Hitoshi Yoshino , Satoshi Tsuchiya , Atsushi Matsuo , Tsutomu Sato , Masahiro Nishimoto , Kyoko Oguri , Hiroko Ogawa , Yoshikazu Nishimura , Yoshiyuki Furuta , Hirotaka Kashiwagi , Nobuyuki Hori , Takuma Kamon , Takuya Shiraishi , Shoshin Yoshida , Takahiro Kawai , Satoshi Tanida , Masahide Aoki
IPC: A61K31/437 , A61P1/16 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/10 , A61P25/16 , A61P25/28 , C07D471/04 , A61K31/506 , C07D519/00 , A61K31/4725 , A61K31/444 , A61K31/496 , A61K31/5386 , A61K31/5377 , A61K31/4709
CPC classification number: C07D471/04 , A61K31/437 , A61K31/444 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/5386 , A61P1/16 , A61P3/04 , A61P3/06 , A61P3/10 , A61P9/10 , A61P25/16 , A61P25/28 , C07D519/00
Abstract: The present invention provides the compound, 3-[(1S,2S)-1-[5-[(4S)-2,2-Dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one, or a pharmaceutically acceptable salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound.
-
公开(公告)号:US20230277547A1
公开(公告)日:2023-09-07
申请号:US18175515
申请日:2023-02-27
Applicant: Vertex Pharmaceuticals Incorporated
Inventor: John Patrick Maxwell , Paul S. Charifson , Qing Tang , Steven M. Ronkin , Katrina Lee Jackson , Albert Charles Pierce , David J. Lauffer , Pan Li , Simon Giroux , Jinwang Xu , Kevin Michael Cottrell , Mark A. Morris , Nathan D. Waal , John J. Court , Wenxin Gu , Hongbo Deng
IPC: A61K31/5377 , C07D513/04 , A61K31/506 , A61K31/5386 , C07D241/40 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12 , C07D471/04 , C07D473/40 , C07D475/00 , C07D487/04 , C07D491/048 , C07D498/08 , C07D413/04 , C07D241/44 , C07D491/052 , C07D241/42 , C07D271/12 , C07D401/12 , C07D413/14 , C07D491/056 , C07D491/08
CPC classification number: A61K31/5377 , C07D513/04 , A61K31/506 , A61K31/5386 , C07D241/40 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12 , C07D471/04 , C07D473/40 , C07D475/00 , C07D487/04 , C07D491/048 , C07D498/08 , C07D413/04 , C07D241/44 , C07D491/052 , C07D241/42 , C07D271/12 , C07D401/12 , C07D413/14 , C07D491/056 , C07D491/08
Abstract: The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
-
公开(公告)号:US11667631B2
公开(公告)日:2023-06-06
申请号:US16302374
申请日:2017-05-16
Inventor: Peng Gao , Wenhua Xiu , Shaobao Wang , Lei Liu , Rudi Bao
IPC: C07D471/04 , A61K35/00 , A61K31/551 , A61K31/5386 , A61K31/5355 , A61K31/444 , A61K31/553
CPC classification number: C07D471/04 , A61K31/444 , A61K31/5355 , A61K31/5386 , A61K31/551 , A61K31/553 , A61K35/00 , Y02P20/55
Abstract: The present invention relates to an FGFR4 inhibitor having a structure represented by formula (I), preparation method therefor, and applications thereof. A series of compounds represented by formula (I) in the present invention have very-strong inhibition effect on the activity of FGFR4 kinase, have very-high selectivity, can be widely used in the preparation of drugs for treating cancers, specially a liver cancer, a stomach cancer, a prostate cancer, a skin cancer, an ovarian cancer, a lung cancer, a breast cancer or a colon cancer, and can be developed into a new-generation FGFR4 inhibitor drug.
-
公开(公告)号:US20190216808A1
公开(公告)日:2019-07-18
申请号:US16204166
申请日:2018-11-29
Applicant: Enanta Pharmaceuticals, Inc.
Inventor: Yao-Ling Qiu , Hui Cao , Wei Li , Xiaowen Peng , Meizhong Jin , Jorden Kass , Xuri Gao , Yat Sun Or
IPC: A61K31/506 , C07D487/04 , C07D451/06 , A61K31/5377 , A61K31/5386 , C07D498/08 , A61K31/505 , A61K45/06 , C07D403/04 , A61K31/683 , C07F9/6558 , C07D417/12 , C07D417/14 , C07D239/20
CPC classification number: A61K31/506 , A61K31/505 , A61K31/5377 , A61K31/5386 , A61K31/683 , A61K45/06 , C07D239/20 , C07D403/04 , C07D417/12 , C07D417/14 , C07D451/06 , C07D487/04 , C07D498/08 , C07F9/65583 , A61K2300/00
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
-
-
-
-
-
-
-
-
-